Method for assessing cancerous state of mammal-derived specimen
CA 2458182 A1 · Owner: Japan As Represented By President Of National Cancer Center · Inventors: Ushijima, Toshikazu; Miyamoto, Kazuaki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of evaluating the degree of canceration of a mammal-origin specimen characterized by having: (1) the first step of measuring the methylation frequency or an indication correlating thereto of Heparan sulfate Dglucosaminyl-3-O-sulfotransferase gene contained in the mammal-origin specimen; and (2) the second step of comparing the methylation frequency or an indication correlating thereto measured above with a control and judging the degree of canceration of the specimen based on the thus obtained difference.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 9, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 9, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 9, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.